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The introduction of a newly developed target therapy for metastatic melanomas poses the challenge to have a good molecular
stratification of those patients who may benefit from this therapeutic option. Practically, BRAF mutation status (V600E) is
commonly screened although other non-V600Emutations (i.e., K-R-M-D) could be found in some patients who respond to therapy
equally to the patients harboring V600E mutations. Furthermore, other mutations, namely, N-RAS, KIT, and GNAQ, should be
sequenced according to distinct melanoma specific subtypes and clinical aspects. In our report, a practical flow chart is described
along with our experience in this field.
After decades of unsatisfactory treatments for advanced
melanoma, in the last five years, new treatment modalities
have been explored that dramatically change the current
clinic scenario. The introduction of targeted therapies for
melanoma is based on the discovery of genes that are linked
to the initiation, progression, and invasion of the tumor [1].
More specifically, somatic mutations in the BRAF, NRAS,
KIT, and GNAQ genes are critical to correctly stage and
manage patients with metastatic disease who can nowadays
benefit from these modern molecular targeted therapies. The
mutations affect receptor tyrosine kinases and the MAPK
andMTOR pathways display different frequencies in distinct
histopathological subtypes of melanoma [2].
Somatic mutations in BRAF have been found in almost
50% of all melanomas [3, 4] and most commonly in
melanomas derived from skin without chronic sun-induced
damage [5]. The result of these mutations (mainly V600E) is
enhanced BRAF kinase activity and increased phosphoryla-
tion of downstream targets, particularly MEK.
In particular, BRAF inhibitors, targeting the common
V600E mutations, have become increasingly popular since
they have a high objective response rate and few side
effects.
In a previous studywe demonstrated that patients harbor-
ing uncommon BRAF V600R-M-D mutations, not included
in the original experimental protocols of BRAF selective
inhibitors, were the responders to the therapy. Surprisingly,
patients harboring non-V600E BRAF mutations revealed
an objective clinical response similar to V600E melanoma
patients [6, 7].
In the clinical setting, BRAF mutations are routinely
screened but when BRAF mutation is not detected,
melanomas should be screened for N-RAS, KIT, and
GNAQmutations.
RAS genes are mutated in up to 20% of melanomas
which are typically thicker and have a higher mitotic rate [8].
Higher frequency ofKITmutation inmelanoma is associated
with older patients and the acral and mucosal melanoma
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Table 1: Patients treated with BRAF and NRAS inhibitors.
Patient ID Gender Age Treatment duration(months) Objective response
Time to progression
(months)
Followup
(months) Status
1 F 60 6 Partial 6 18 Dead
2 F 61 26 In response 26 29 Alive
3 F 66 4 Partial 4 13 Dead
4 F 51 14 Partial 14 19 Alive
5 M 59 4 Partial 4 5 Dead
6 F 67 6 Partial 6 7 Dead
7 M 51 6 Partial 6 18 Alive
8 M 70 6 Partial 6 11 Dead
9 F 68 23 Partial In response 23 Alive
10 F 62 6 Partial 6 11 Alive
11 F 81 8 Partial 7 8 Dead
12 M 56 2 None 3 3 Dead
13 F 51 5 Partial 5 5 Dead
14 F 58 18 Partial In response 18 Alive
15 M 68 6 Partial 14 6 Dead
16 M 43 9 Partial 3 16 Dead
17 M 62 6 Partial In response 6 Alive
18 M 58 8 Partial In response 18 Dead
19 M 38 2 Partial 2 3 Dead
20 M 66 12 Partial 10 12 Alive
21 M 65 6 Partial In response 6 Alive
22 M 79 7 In response Stable disease 7 Alive
23 M 75 8 Partial 6 8 Dead
1 N-ras M 69 10 Partial 10 12 Alive
2 N-ras M 56 6 Stable 6 7 Alive
subtypes [8]. Somatic mutations in the GNAQ and GNA11
genes are found in 80% of uveal melanomas [9]. Nowadays,
patients withN-RAS,KIT, andGNAQmutated tumors can be
enrolled in clinical trials of specific inhibitors [2, 8–11].
In the experience of our institution, thirty-two BRAF
mutated melanomas (32%) were detected among 99 melano-
mas screened for geneticmutations. Among BRAFmutation-
negative melanomas, 6 N-RAS mutations (four Q61R, one
Q61K, and one Q61L) and 3 KIT mutations (N822K) were
found. The lower BRAF mutation rate found in our study
compared to the literature might be due to a selection bias
since we screened only patients with metastatic disease.
Hot spot V600E mutations were found in 27 patients.
V600Rmutation and double (V600E-V600M)mutationwere
identified in two melanomas. In five cases, V600K mutations
were found. Two screening failures were noted.
Twenty-three patients with BRAF mutated metastatic
melanoma were enrolled in the protocol with BRAF
inhibitors for compassionate use at the University of Mod-
ena. Two N-RAS mutated patients were enrolled in an
alternative anti-NRAS protocol in another University. Mean
progression-free survival for BRAF positive patients at fol-
lowup of 8 weeks was 7.6 months (Table 1) (Figure 1). There
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Figure 1: Clinical features of patients treated with BRAF inhibitors.
was no statistically significant difference in the duration of
the objective tumor response among different BRAF status
groupings. An objective response with few side effects was
observed in all except one patient (Table 2).
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Table 2: Patients treated with BRAF inhibitors: frequencies of side
effects.
Side effects Frequency (%)
Arthralgia 54%
Nausea 34%
Skin erythema 28%
Vomiting 14%
Headache 13%
Fatigue 11%
Keratoacanthomas 2%
Hypertransaminasemia 2%
Alopecia 1%
QTc prolongation 1%
Based on our preliminary findings, we propose a stepwise
model to characterize the mutational status of melanomas.
(1) Screen for V600E BRAF mutation in melanoma
patients with advanced disease (i.e., unresectable
stages III and IV) as well as those at high risk of
disease progression (stages IIIB and IIIC).
(2) In case of negative-V600E BRAF mutation, look for
other non-V600E BRAF mutations (i.e., K, M, R, D).
(3) Melanomas not showing BRAF mutations should be
investigated for N-RASmutations.
(4) Double-negative BRAF and N-RAS melanomas
should be further explored for KIT mutations or
amplifications. This is even more relevant for acral
and mucosal melanomas that should be investigated
for both BRAF and KIT mutations at the first step.
(5) Triple-negative melanomas may benefit from GNAQ
mutation evaluation, especially for uveal melanoma.
For melanoma, like other cancers, tailored therapies are
dramatically changing the current approaches for treating
patients with metastatic disease. However, the heterogeneous
molecular defects in melanoma account for the development
of drug resistance and thus the different clinical objective
responses of targeted therapies. It is known that resistance
to BRAF inhibitors is due to either the acquisition of sec-
ondary mutations in the BRAF gene or upregulation of other
molecular pathways such as platelet-derived growth factor
receptor 𝛽 or N-RAS, the consequences of which lead to
resistance to MEK and ERK inhibitors [12, 13]. Independent
research teams have identified three mechanisms by which
melanoma can develop resistance to BRAF inhibitors [13,
14]. The findings suggest that BRAF inhibitors will need
to be combined with other types of drugs, although future
studies will have to determine the relative frequency of each
mechanism. To conclude, future efforts will be directed not
only to develop multitargeted therapies (i.e., BRAF andMEK
inhibitors) but also to further investigate the combination of
target treatments and promising immune-therapy approach.
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